{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:06:04Z","timestamp":1766729164761,"version":"3.48.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"DOI":"10.7759\/cureus.100094","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:02:47Z","timestamp":1766728967000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Improvements in Quality of Life With Disease-Modifying Anti-rheumatic Drugs in Seropositive and Seronegative Rheumatoid Arthritis"],"prefix":"10.7759","author":[{"given":"Avinash","family":"Muraleedharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Chaubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalu","family":"A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen JS","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016, 388:2023-38. 10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"ref2","article-title":"Chronic rheumatic disorders","author":"Karlson EW","year":"1996","unstructured":"Karlson EW, Katz JN, Liang MH. Chronic rheumatic disorders. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd Edition. Spilker B (ed): Lippincott-Raven, Philadelphia, PA; 1996. 1029-37."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-7-201004060-00010","article-title":"Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis","volume":"152","author":"Whiting PF","year":"2010","unstructured":"Whiting PF, Smidt N, Sterne JA, et al.. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010, 152:456-64. 10.7326\/0003-4819-152-7-201004060-00010","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantap\u00e4\u00e4-Dahlqvist S","year":"2003","unstructured":"Rantap\u00e4\u00e4-Dahlqvist S, de Jong BA, Berglin E, et al.. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48:2741-9. 10.1002\/art.11223","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010, 69:1580-8. 10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.02.013","article-title":"Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity","volume":"94","author":"Han B","year":"2014","unstructured":"Han B, Diogo D, Eyre S, et al.. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet. 2014, 94:522-32. 10.1016\/j.ajhg.2014.02.013","journal-title":"Am J Hum Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.28","article-title":"Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease?","volume":"7","author":"Daha NA","year":"2011","unstructured":"Daha NA, Toes RE. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease?. Nat Rev Rheumatol. 2011, 7:202-3. 10.1038\/nrrheum.2011.28","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.194","article-title":"Rheumatoid arthritis: seronegative and seropositive RA: alike but different?","volume":"11","author":"Ajeganova S","year":"2015","unstructured":"Ajeganova S, Huizinga TW. Rheumatoid arthritis: seronegative and seropositive RA: alike but different?. Nat Rev Rheumatol. 2015, 11:8-9. 10.1038\/nrrheum.2014.194","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208873","article-title":"Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria","volume":"76","author":"Nordberg LB","year":"2017","unstructured":"Nordberg LB, Lillegraven S, Lie E, et al.. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria. Ann Rheum Dis. 2017, 76:341-5. 10.1136\/annrheumdis-2015-208873","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20207","article-title":"Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies","volume":"62","author":"Farragher TM","year":"2010","unstructured":"Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken). 2010, 62:664-75. 10.1002\/acr.20207","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"Katchamart W","year":"2015","unstructured":"Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int. 2015, 35:1693-9. 10.1007\/s00296-015-3271-8","journal-title":"Rheumatol Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2329-5","article-title":"A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients","volume":"32","author":"Geng Y","year":"2012","unstructured":"Geng Y, Zhou W, Zhang ZL. A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients. Rheumatol Int. 2012, 32:3897-901. 10.1007\/s00296-011-2329-5","journal-title":"Rheumatol Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo ML","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-8. 10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)90884-8","article-title":"Measurement of pain","volume":"2","author":"Huskisson EC","year":"1974","unstructured":"Huskisson EC. Measurement of pain. Lancet. 1974, 2:1127-31. 10.1016\/s0140-6736(74)90884-8","journal-title":"Lancet"},{"key":"ref16","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware JE Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30:473-83.","journal-title":"Med Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_53_20","article-title":"Quantification of health-related quality of life among patients with rheumatoid arthritis: an institution-based study in Kolkata, West Bengal","volume":"9","author":"Mandal M","year":"2020","unstructured":"Mandal M, Dasgupta A, Dutt D, Taraphdar P, Ghosh P, Paul B. Quantification of health-related quality of life among patients with rheumatoid arthritis: an institution-based study in Kolkata, West Bengal. J Family Med Prim Care. 2020, 9:3970-6. 10.4103\/jfmpc.jfmpc_53_20","journal-title":"J Family Med Prim Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.509","article-title":"Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period","volume":"46","author":"Doran MF","year":"2002","unstructured":"Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002, 46:625-31. 10.1002\/art.509","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23497","article-title":"Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward","volume":"70","author":"Boer AC","year":"2018","unstructured":"Boer AC, Boonen A, van der Helm van Mil AH. Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward. Arthritis Care Res (Hoboken). 2018, 70:987-96. 10.1002\/acr.23497","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195550","article-title":"Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study","volume":"13","author":"Choi S","year":"2018","unstructured":"Choi S, Lee KH. Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study. PLoS One. 2018, 13:e0195550. 10.1371\/journal.pone.0195550","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140082","article-title":"Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis","volume":"41","author":"Barra L","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, et al.. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014, 41:2361-9. 10.3899\/jrheum.140082","journal-title":"J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/ar4439","article-title":"ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial","volume":"16","author":"Seegobin SD","year":"2014","unstructured":"Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, Scott IC. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014, 16:R13. 10.1186\/ar4439","journal-title":"Arthritis Res Ther"},{"key":"ref23","article-title":"Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski M","year":"2002","unstructured":"Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002, 8:231-40.","journal-title":"Am J Manag Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial","volume":"64","author":"Moreland LW","year":"2012","unstructured":"Moreland LW, O'Dell JR, Paulus HE, et al.. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012, 64:2824-35. 10.1002\/art.34498","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/art.20351","article-title":"Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study","volume":"50","author":"Korpela M","year":"2004","unstructured":"Korpela M, Laasonen L, Hannonen P, et al.. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004, 50:2072-81. 10.1002\/art.20351","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial","volume":"353","author":"M\u00f6tt\u00f6nen T","year":"1999","unstructured":"M\u00f6tt\u00f6nen T, Hannonen P, Leirisalo-Repo M, et al.. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999, 353:1568-73. 10.1016\/s0140-6736(98)08513-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439733-comparison-of-improvements-in-quality-of-life-with-disease-modifying-anti-rheumatic-drugs-in-seropositive-and-seronegative-rheumatoid-arthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:02:48Z","timestamp":1766728968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439733-comparison-of-improvements-in-quality-of-life-with-disease-modifying-anti-rheumatic-drugs-in-seropositive-and-seronegative-rheumatoid-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.100094","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}